Falsely increased immunoassay measurements of total and unbound phenytoin in critically III uremic patients receiving fosphenytoin

William L. Roberts, Barun K De, John P. Coleman, Thomas M. Annesley

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Fosphenytoin, a phosphate ester prodrug of phenytoin, is metabolized to phenytoin in vivo. Phenytoin metabolites accumulate in renal insufficiency and cross-react in some phenytoin immunoassays. Our aim was to determine the accuracy of phenytoin immunoassays in renal patients treated with fosphenytoin. Methods: We measured phenytoin with HPLC and with the aca, ACS:180, TDx phenytoin II, Vitros, and AxSYM methods. Specimens were collected 2-120 h after fosphenytoin administration from 17 patients with renal insufficiency. Results: The AxSYM, TDx phenytoin II, ACS:180, and Vitros assays displayed falsely increased phenytoin results up to 20 times higher than the HPLC results. The aca Star results for these specimens were comparable to the HPLC results. Although fosphenytoin can cross-react with phenytoin immunoassays, no fosphenytoin was detected by a sensitive HPLC method in any sample that was tested for its presence. Conclusion: These results are consistent with the formation of one or more novel metabolites or adducts of fosphenytoin that accumulate in some critically ill patients with renal insufficiency and that display significant cross-reactivity with some, but not all, phenytoin immunoassay methods.

Original languageEnglish (US)
Pages (from-to)829-837
Number of pages9
JournalClinical Chemistry
Volume45
Issue number6 I
StatePublished - 1999
Externally publishedYes

Fingerprint

Phenytoin
Immunoassay
High Pressure Liquid Chromatography
Renal Insufficiency
Metabolites
fosphenytoin
Prodrugs
Critical Illness
Stars
Assays
Esters
Phosphates
Kidney

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Falsely increased immunoassay measurements of total and unbound phenytoin in critically III uremic patients receiving fosphenytoin. / Roberts, William L.; De, Barun K; Coleman, John P.; Annesley, Thomas M.

In: Clinical Chemistry, Vol. 45, No. 6 I, 1999, p. 829-837.

Research output: Contribution to journalArticle

Roberts, William L. ; De, Barun K ; Coleman, John P. ; Annesley, Thomas M. / Falsely increased immunoassay measurements of total and unbound phenytoin in critically III uremic patients receiving fosphenytoin. In: Clinical Chemistry. 1999 ; Vol. 45, No. 6 I. pp. 829-837.
@article{17a37ad88c0c4e9bb01e49b3b790e054,
title = "Falsely increased immunoassay measurements of total and unbound phenytoin in critically III uremic patients receiving fosphenytoin",
abstract = "Background: Fosphenytoin, a phosphate ester prodrug of phenytoin, is metabolized to phenytoin in vivo. Phenytoin metabolites accumulate in renal insufficiency and cross-react in some phenytoin immunoassays. Our aim was to determine the accuracy of phenytoin immunoassays in renal patients treated with fosphenytoin. Methods: We measured phenytoin with HPLC and with the aca, ACS:180, TDx phenytoin II, Vitros, and AxSYM methods. Specimens were collected 2-120 h after fosphenytoin administration from 17 patients with renal insufficiency. Results: The AxSYM, TDx phenytoin II, ACS:180, and Vitros assays displayed falsely increased phenytoin results up to 20 times higher than the HPLC results. The aca Star results for these specimens were comparable to the HPLC results. Although fosphenytoin can cross-react with phenytoin immunoassays, no fosphenytoin was detected by a sensitive HPLC method in any sample that was tested for its presence. Conclusion: These results are consistent with the formation of one or more novel metabolites or adducts of fosphenytoin that accumulate in some critically ill patients with renal insufficiency and that display significant cross-reactivity with some, but not all, phenytoin immunoassay methods.",
author = "Roberts, {William L.} and De, {Barun K} and Coleman, {John P.} and Annesley, {Thomas M.}",
year = "1999",
language = "English (US)",
volume = "45",
pages = "829--837",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "6 I",

}

TY - JOUR

T1 - Falsely increased immunoassay measurements of total and unbound phenytoin in critically III uremic patients receiving fosphenytoin

AU - Roberts, William L.

AU - De, Barun K

AU - Coleman, John P.

AU - Annesley, Thomas M.

PY - 1999

Y1 - 1999

N2 - Background: Fosphenytoin, a phosphate ester prodrug of phenytoin, is metabolized to phenytoin in vivo. Phenytoin metabolites accumulate in renal insufficiency and cross-react in some phenytoin immunoassays. Our aim was to determine the accuracy of phenytoin immunoassays in renal patients treated with fosphenytoin. Methods: We measured phenytoin with HPLC and with the aca, ACS:180, TDx phenytoin II, Vitros, and AxSYM methods. Specimens were collected 2-120 h after fosphenytoin administration from 17 patients with renal insufficiency. Results: The AxSYM, TDx phenytoin II, ACS:180, and Vitros assays displayed falsely increased phenytoin results up to 20 times higher than the HPLC results. The aca Star results for these specimens were comparable to the HPLC results. Although fosphenytoin can cross-react with phenytoin immunoassays, no fosphenytoin was detected by a sensitive HPLC method in any sample that was tested for its presence. Conclusion: These results are consistent with the formation of one or more novel metabolites or adducts of fosphenytoin that accumulate in some critically ill patients with renal insufficiency and that display significant cross-reactivity with some, but not all, phenytoin immunoassay methods.

AB - Background: Fosphenytoin, a phosphate ester prodrug of phenytoin, is metabolized to phenytoin in vivo. Phenytoin metabolites accumulate in renal insufficiency and cross-react in some phenytoin immunoassays. Our aim was to determine the accuracy of phenytoin immunoassays in renal patients treated with fosphenytoin. Methods: We measured phenytoin with HPLC and with the aca, ACS:180, TDx phenytoin II, Vitros, and AxSYM methods. Specimens were collected 2-120 h after fosphenytoin administration from 17 patients with renal insufficiency. Results: The AxSYM, TDx phenytoin II, ACS:180, and Vitros assays displayed falsely increased phenytoin results up to 20 times higher than the HPLC results. The aca Star results for these specimens were comparable to the HPLC results. Although fosphenytoin can cross-react with phenytoin immunoassays, no fosphenytoin was detected by a sensitive HPLC method in any sample that was tested for its presence. Conclusion: These results are consistent with the formation of one or more novel metabolites or adducts of fosphenytoin that accumulate in some critically ill patients with renal insufficiency and that display significant cross-reactivity with some, but not all, phenytoin immunoassay methods.

UR - http://www.scopus.com/inward/record.url?scp=0033066414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033066414&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 829

EP - 837

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 6 I

ER -